Advances in the understanding of androgen receptor structure and function and in the development of next-generation AR-targeted therapeutics

被引:1
|
作者
Effah, Wendy [1 ]
Khalil, Marjana [1 ]
Hwang, Dong-Jin [2 ]
Miller, Duane D. [2 ]
Narayanan, Ramesh [1 ,3 ]
机构
[1] Univ Tennessee Hlth Sci Ctr, Coll Med, Dept Med, Memphis, TN 38163 USA
[2] Univ Tennessee Hlth Sci Ctr, Coll Pharm, Dept Pharmaceut Sci, Memphis, TN USA
[3] Univ Tennessee Hlth Sci Ctr, UTHSC Ctr Canc Res, Memphis, TN 38163 USA
关键词
Androgen receptor (AR); AR splice variants; Androgen receptor N -terminus; Selective AR degraders; Prostate cancer; Kennedy's disease; Condensates; LIQUID PHASE-SEPARATION; BULBAR MUSCULAR-ATROPHY; TRANSGENIC MOUSE MODEL; PROSTATE-CANCER; INSENSITIVITY SYNDROME; CLINICAL-IMPLICATIONS; TESTOSTERONE LEVELS; GENE-MUTATIONS; BREAST-CANCER; VARIANTS;
D O I
10.1016/j.steroids.2024.109486
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Androgen receptor (AR) and its ligand androgens are important for development and physiology of various tissues. AR and its ligands also play critical role in the development of various diseases, making it a valuable therapeutic target. AR ligands, both agonists and antagonists, are being widely used to treat pathological conditions, including prostate cancer and hypogonadism. Despite AR being studied widely over the last five decades, the last decade has seen striking advances in the knowledge on AR and discoveries that have the potential to translate to the clinic. This review provides an overview of the advances in AR biology, AR molecular mechanisms of action, and next generation molecules that are currently in development. Several of the areas described in the review are just unraveling and the next decade will bring more clarity on these developments that will put AR at the forefront of both basic biology and drug development.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Targeted next-generation sequencing identification of mutations in patients with disorders of sex development
    Dong, Yanling
    Yi, Yuting
    Yao, Hong
    Yang, Ziying
    Hu, Huamei
    Liu, Jiucheng
    Gao, Changxin
    Zhang, Ming
    Zhou, Liying
    Asan
    Yi, Xin
    Liang, Zhiqing
    BMC MEDICAL GENETICS, 2016, 17
  • [22] Development and Validation of a Targeted Next-Generation Sequencing Gene Panel for Children With Neuroinflammation
    McCreary, Dara
    Omoyinmi, Ebun
    Hong, Ying
    Mulhern, Ciara
    Papadopoulou, Charalampia
    Casimir, Marina
    Hacohen, Yael
    Nyanhete, Rodney
    Ahlfors, Helena
    Cullup, Thomas
    Lim, Ming
    Gilmour, Kimberly
    Mankad, Kshitij
    Wassmer, Evangeline
    Berg, Stefan
    Hemingway, Cheryl
    Brogan, Paul
    Eleftheriou, Despina
    JAMA NETWORK OPEN, 2019, 2 (10)
  • [23] Next-Generation Androgen Receptor-Signaling Inhibitors for Prostate Cancer: Considerations for Older Patients
    Feng, Zizhen
    Graff, Julie N.
    DRUGS & AGING, 2021, 38 (02) : 111 - 123
  • [24] Next-Generation Androgen Receptor-Signaling Inhibitors for Prostate Cancer: Considerations for Older Patients
    Zizhen Feng
    Julie N. Graff
    Drugs & Aging, 2021, 38 : 111 - 123
  • [25] The MHC in the era of next-generation sequencing: Implications for bridging structure with function
    Petersdorf, Effie W.
    O'hUigin, Colm
    HUMAN IMMUNOLOGY, 2019, 80 (01) : 67 - 78
  • [26] TAS3681, a new type of androgen receptor antagonist, disrupts aberrant AR signaling that drives tumor resistance to AR-targeted therapies by downregulating full-length and splice variant AR
    Kajiwara, D.
    Minamiguchi, K.
    Seki, M.
    Mizutani, H.
    Yamamura, K.
    Okajima, S.
    Sasaki, E.
    Utsugi, T.
    Iwasawa, Y.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S127 - S127
  • [27] Development and Analytical Validation of a Targeted Next-Generation Sequencing Panel to Detect Actionable Mutations for Targeted Therapy
    Wang, Dandan
    Ma, Kai
    Deng, Wei
    Li, Jingyu
    Xiang, Shaohua
    Zhang, Yang
    Fu, Ying
    Dai, Heng
    Huang, Bingding
    ONCOTARGETS AND THERAPY, 2021, 14 : 2423 - 2431
  • [28] Epigenetic therapeutics in dental pulp treatment: Hopes, challenges and concerns for the development of next-generation biomaterials
    Duncan, Henry F.
    Kobayashi, Yoshifumi
    Kearney, Michaela
    Shimizu, Emi
    BIOACTIVE MATERIALS, 2023, 27 : 574 - 593
  • [29] Drug induced resistant tumor models enable the development of next-generation anticancer therapeutics.
    Ni, Ting
    Zhang, Zhixiang
    Tang, Xuzhen
    Shi, Wenting
    Gu, Qingyang
    Ji, Qunsheng
    CANCER RESEARCH, 2021, 81 (13)
  • [30] Is Biotechnological Next-generation Therapeutics Promising Enough in Clinical Development to Treat Advanced Colon Cancer?
    Malayaperumal, Sarubala
    Sriramulu, Sushmitha
    Banerjee, Antara
    Makalakshmi, M. K.
    Pathak, Surajit
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2021, 22 (10) : 1287 - 1301